 |
|
Pneumococcal Vaccine After 15 Years of UseAnother View
David S. Fedson, MD;
Eugene D. Shapiro, MD;
F. Marc LaForce, MD;
Maurice A. Mufson, MD;
Daniel M. Musher, MD;
John S. Spika, MD;
Robert F. Breiman, MD;
Claire V. Broome, MD
Arch Intern Med. 1994;154(22):2531-2535.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
|
|
IN A recent Commentary, Hirschmann and Lipsky1 reviewed pneumococcal vaccine after 15 years of use in the United States. Following their evaluation of prospective vaccine trials, retrospective studies, and projections of vaccine effectiveness, they stated that "no conclusive evidence has yet emerged that the pneumococcal vaccine is effective in any group in the United States." In their judgment, "the evidence justifies not vaccinating immunocompromised or elderly populations" with pneumococcal vaccine.
While most observers would agree that the available evidence on the clinical effectiveness of pneumococcal vaccination is incomplete, the evidence has been the subject of ongoing critical review by several expert groups, including the Advisory Committee on Immunization Practices,2 the American College of Physicians/ Infectious Diseases Society of America Task Force on Adult Immunization,3 the National Advisory Committee on Immunization in Canada,4 and a Technical Advisory Group to the World Health Organization Regional Office for Europe.5
. . . [Full Text PDF of this Article]
Author Affiliations
Box 494 University of Virginia Health Sciences Center Charlottesville, VA 22908; New Haven, Conn; Rochester, NY; Huntington, WVa; Houston, Tex; Ottawa, Ontario; Atlanta, Ga
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
|
